About Genomtec
Genomtec is a company based in Wrocław (Poland) founded in 2016. Genomtec has raised $4.38 million across 6 funding rounds from investors including European Union, PARP and National Research Development Corporation. Genomtec offers products and services including Genomtec ID, Genomtec Tumor, Genomtec SARS-CoV-2 EvaGreen, and Genomtec RT-LAMP Duo Kit. Genomtec operates in a competitive market with competitors including Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
- Headquarter Wrocław, Poland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genomtec S.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.38 M (USD)
in 6 rounds
-
Latest Funding Round
$5.49 M (USD), Grant
Dec 27, 2023
-
Investors
European Union
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Genomtec
Genomtec offers a comprehensive portfolio of products and services, including Genomtec ID, Genomtec Tumor, Genomtec SARS-CoV-2 EvaGreen, and Genomtec RT-LAMP Duo Kit.
Mobile platform for point-of-care genetic diagnostics.
Platform for genetic analysis in oncology applications.
Kit for detecting SARS-CoV-2 through genetic methods.
Kit for rapid genetic testing in various applications.
People of Genomtec
Unlock access to complete
Unlock access to complete
Funding Insights of Genomtec
Genomtec has successfully raised a total of $4.38M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $5.49 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genomtec
Genomtec has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, PARP and National Research Development Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Management consulting and business management services are provided.
|
Locked | Locked | Locked |
Investor details for Genomtec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genomtec
Investment portfolio details for Genomtec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genomtec
Detailed financials for Genomtec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genomtec Comparisons
Peer comparison for Genomtec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genomtec
Genomtec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| Locked | Locked | Locked |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
Detailed competitors of Genomtec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genomtec
Complete news archive for Genomtec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomtec
Genomtec was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Genomtec is headquartered in Wrocław, Poland. It is registered at Wrocław, Lower Silesian Voivodeship, Poland.
Damian Andrzejewski is the current CEO of Genomtec.
Genomtec is a funded company, having raised a total of $4.38M across 6 funding rounds to date.
Genomtec was founded in 2016 in Wroclaw, Poland, and operates in the molecular diagnostics sector. A handheld point-of-care device is offered for isothermal amplification and detection of DNA and RNA fragments. Sample preparation is not required, and up to 10 samples or probes can be multiplexed in a single run. The focus remains on nucleic acid testing applications.
Genomtec's top competitors include Qiagen, Parse Biosciences and NuProbe.
Genomtec offers Genomtec ID, Genomtec Tumor, Genomtec SARS-CoV-2 EvaGreen, and Genomtec RT-LAMP Duo Kit.
Genomtec has 5 investors. Key investors include European Union, PARP, National Research Development Corporation, KnowledgeHub, and EIC Fund.